| Customization: | Available |
|---|---|
| CAS No.: | 62304-98-7 |
| Formula: | C129h215n33o55 |
|
Still deciding? Get samples of US$ 8.5/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Description:
Thymalfasin (thymosin-α1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with inter feron-α for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.
1. For the treatment of chronic hepatitis B.
2. A vaccine immune response enhancer as an immunocompromised patient. Immune system function is inhibited, including chronic hemodialysis and elderly patients, this product can enhance the immune response of patients with viral vaccines, such as influenza vaccine or hepatitis B vaccine.
A number of in vitro tests showed that the goods through the stimulation of peripheral blood lymphocytes promoting T lymphocyte mitogen original maturity, increase antigen or mitogen-activated T cells secrete inter feron-α, inter feron-γ and interleukin-2, interleukin-3, etc. lymphokines level, while increasing the T cell surface receptor level lymphokines. This product can also through the activation of CD4 cells, enhancing human allogeneic and autologous mixed lymphocyte reaction. It can be used to increase NK cells before aggregation, and enhanced cytotoxicity inter feron can make it. In vivo tests showed that product can increase by Con A activated lymphocytes in mice interleukin-2 receptor expression levels, while increasing the secretion of interleukin-2 levels.
){kind=link}